Meta-analysis of the efficacy and safety of adding an angiotensin receptor blocker (ARB) to a calcium channel blocker (CCB) following ineffective CCB monotherapy

Jin Ma¹, Xiao-Yan Wang², Zhi-De Hu³, Zhi-Rui Zhou⁴,⁵, Paul Schoenhagen⁶, Hao Wang¹

¹Department of Cardiology, Yangpu Hospital, Tongji University, Shanghai 20090, China; ²Graduate School, Dalian Medical University, Dalian 116044, China; ³Department of Laboratory Medicine, General Hospital of Ji’nan Military Region, Ji’nan 250031, China; ⁴Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; ⁵Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; ⁶Cleveland Clinic, Imaging Institute and Heart & Vascular Institute, Cleveland, USA

Contributions: (I) Conception and design: J Ma, H Wang; (II) Administrative support: X Wang; (III) Provision of study materials or patients: XY Wang; (IV) Collection and assembly of data: XY Wang; (V) Data analysis and interpretation: ZD Hu, ZR Zhou; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Hao Wang, MD. Department of Cardiology, Yangpu Hospital, Tongji University, No 450, Tengyue Rd, Shanghai 20090, China. Email: Dr_wanghao@163.com; 794319697@qq.com.

Background: We conducted this meta-analysis to systematically review and analyze the clinical benefits of angiotensin receptor blocker (ARB) combined with calcium channel blocker (CCB) following ineffective CCB monotherapy.

Methods: PubMed was searched for articles published until August 2015. Randomized controlled trials (RCTs) evaluating the clinical benefits of ARB combined with CCB following ineffective CCB monotherapy were included. The primary efficacy endpoint of the studies was normal rate of blood pressure, the secondary efficacy endpoints were the response rate and change in blood pressure from baseline. The safety endpoint of the studies was incidence of adverse events. Differences are expressed as relative risks (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes and weighted mean differences (WMDs) with 95% CIs for continuous outcomes. Heterogeneity across studies was tested by using the I² statistic.

Results: Seven RCTs were included and had sample sizes ranging from 185 to 1,183 subjects (total: 3,909 subjects). The pooled analysis showed that the on-target rate of hypertension treatment was significantly higher in the amlodipine + ARB group than in the amlodipine monotherapy group (RR =1.59; 95% CI, 1.31–1.91; P<0.01). The response rate of systolic blood pressure (SBP) (RR =1.28; 95% CI, 1.04–1.58; P<0.01) and diastolic blood pressure (DBP) (RR =1.27; 95% CI, 1.12–1.44; P=0.04) were significantly higher in the amlodipine + ARB group than in the amlodipine monotherapy group. The change in SBP (RR =−3.56; 95% CI, −7.76–0.63; P=0.10) and DBP (RR =−3.03; 95% CI, −6.51–0.45; P=0.09) were higher in hypertensive patients receiving amlodipine + ARB but the difference did not reach statistical significance. ARB + amlodipine treatment carried a lower risk of adverse events relative to amlodipine monotherapy (RR =0.88; 95% CI, 0.80–0.96; P<0.01).

Conclusions: The results of our meta-analysis demonstrate that adding an ARB to CCB after initial ineffective CCB monotherapy, significantly improved blood pressure control and the percentage of on-target hypertension treatment with significantly reduced incidence of adverse events compared with continued CCB monotherapy.

Keywords: Hypertension; angiotensin receptor antagonists; calcium channel blockers (CCB); drug combinations; meta-analysis

Submitted Oct 05, 2015. Accepted for publication Nov 30, 2015.
View this article at: http://dx.doi.org/10.3978/j.issn.2072-1439.2015.12.39
Introduction

Hypertension is a major risk factor for cardiovascular morbidity and mortality (1-4) and accounts for 13.5% of all-cause mortality worldwide. Strict blood pressure control, as recommended by professional guidelines, significantly reduces the risk of cardiovascular events, stroke and death (5,6). However, at present, the percentage of hypertensive patient achieving recommended targets is below 35% (7).

Guidelines for the management of hypertension (8,9) recommend that using initial monotherapy for treatment-naive patients with addition of a second drug if monotherapy is ineffective. Calcium channel blockers (CCBs) are among recommended first-line treatment options. Advantageous pleiotropic effects of CCB treatment include slowing of atherosclerosis progression (10), improvements of cardiac (11) and renal function (12), reduction of diabetes risk (13). Treatment with CCB is associated with improved prognosis (14-16). However, 75% of hypertensive patients fail to reach the recommended blood pressure targets with monotherapy, and eventually require combination therapy (17). Prior studies demonstrated that adding an angiotensin receptor blocker (ARB) to CCB after initial ineffective CCB monotherapy, is well tolerated and can improve the percentage of patient achieving good blood pressure control (18). However, large-scale, randomized, controlled studies, evaluating the clinical benefits of converting to ARB + CCB following ineffective CCB monotherapy, are lacking.

We therefore conducted this meta-analysis to systematically review and analyze the clinical benefits of ARB + CCB following ineffective CCB monotherapy.

Methods

Literature search and retrieval

Two authors searched relevant studies published in PubMed until August 2015 using Medical Subject Headings (Mesh) and keyword searches. For Mesh, the search format was “Calcium Channel Blockers” [Mesh], “Angiotensin II Type 1 Receptor Blockers” [Mesh], and “Hypertension” [Mesh]; and the keywords were nifedipine, felodipine, amlodipine, lacidipine, nimodipine, nitrendipine, nicardipine, diltiazem, verapamil, calcium channel blockers, as well as losartan, valsartan, olmesartan, telmisartan, candesartan, irbesartan, angiotensin receptor inhibitor. In addition, we verified the references in the papers retrieved and included those that met the inclusion criteria in this meta-analysis.

Literature screening

The literature was screened according to the following criteria: (I) study design: randomized controlled trials (RCTs); (II) study population: hypertensive patients with ineffective CCB monotherapy; (III) treatment: CCB, with or without ARB; (IV) prognosis evaluation: improvement of (systolic or diastolic) blood pressure, blood pressure response rate, on-target rate of hypertension treatment, and the incidence of adverse events in hypertension patients receiving different antihypertensive treatments.

Data extraction

Two authors independently extracted the following data: lead author, year of publication, the characteristics of the population enrolled, the number of patients enrolled, study design, the experimental group [number of patients, drug(s) and dose(s)], the control group [number of patients, drug(s) and dose(s)], treatment time, definition of blood pressure, blood pressure response rate, the rate of normal blood pressure and related definition, and the incidence of adverse events and related definitions. Extracted data were entered into a standard EXCEL file (Microsoft Corp.) and were checked by another author of this paper. During data extraction, any discrepancy was resolved through discussions between the authors of this paper.

The primary efficacy endpoint of the studies was normal rate of blood pressure, the secondary efficacy endpoints were the response rate and change in blood pressure from baseline. The safety endpoint of the studies was incidence of adverse events.

Quality evaluation

After selection, the same two authors assessed the included RCTs independently for risk of bias using the Cochrane risk-of-bias tool (19). We assigned values of low, unclear or high risk of bias to the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other biases. Disagreements were resolved by consensus.

Statistical analysis

Differences are expressed as relative risks (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes and
weighted mean differences (WMDs) with 95% CIs for continuous outcomes. Heterogeneity across studies was tested by using the $I^2$ statistic, which is a quantitative measure of inconsistency across studies. Studies with $I^2$ statistics of 25–50% were considered to have low heterogeneity, those with $I^2$ statistics of 50–75% were considered to have moderate heterogeneity, and those with $I^2$ statistics of 75% or greater were considered to have high heterogeneity (20). A fixed effect model was used regardless of heterogeneity. A P value <0.05 was considered statistically significant, except where otherwise specified. All statistical analyses were performed using Review Manager (Rev Man version 5.2; Nordic Cochrane Centre, Cochrane Collaboration).

**IRB approval**

This study used publicly available information and was therefore exempt from IRB approval.

**Results**

**Study selection**

A total of 391 papers were retrieved, of which 382 papers were excluded based on review of title and abstract. Four papers were subsequently excluded based on full text review (21-24) [three papers (21,23,24) lacked a control group, and one study (22) did not enroll patients with ineffective CCB treatment]. Two papers were added after manual search and retrieval (25,26). Therefore, a total of 7 studies were included in this meta-analysis (25-31) (Figure 1).

**Characteristics of selected studies**

The characteristics of the 7 RCTs included are shown in Table 1. These RCTs were published in 2009-2012, with sample sizes of 185 to 1,183 subjects (total: 3,909 subjects). Six (25-27,29-31) of the seven included studies provided the percentage of on-target treatment before and after randomized treatment, six studies (25-30) provided blood pressure response rates before and after randomized treatment, and all seven studies (25-31) reported information about adverse events. The quality ratings of the selected studies are shown in Table 2.

**Primary efficacy endpoint: percentage of on-target hypertension treatment**

Of the six studies that provided the percentage of on-target hypertension treatment, the Neldam-2011 (30) and Volpe-2009 (31) studies included four subgroups, and we extracted only information about the amlodipine 5 mg group and the amlodipine 5 mg + telmisartan 80 mg group for our analysis. We defined target blood pressure as BP <140/90 mmHg.

Figure 2 summarizes the result of the on-target rate of hypertension treatment using a random effects model. This meta-analysis included a total of 3,440 subjects, including 1,662 subjects in the amlodipine group and 1,778 subjects in the amlodipine + ARB group. The results showed that the on-target rate of hypertension treatment was significantly higher in the amlodipine + ARB group than in the amlodipine monotherapy group (RR =1.59; 95% CI, 1.31–1.91; P<0.01). There was significant heterogeneity among the six studies ($I^2=0.85$).

**Secondary efficacy endpoint: blood pressure response rate and changes in blood pressure**

**Blood pressure response rate**

Of the six studies that provided blood pressure response rates, the Neldam-2011 (30) study included four subgroups; we extracted only information about the amlodipine 5 mg group and the amlodipine 5 mg + telmisartan 80 mg group for our analysis. We performed a meta-analysis of the response rates of systolic and diastolic blood pressure (DBP), where the response of systolic blood pressure (SBP) to drug
### Table 1 Characteristics of included studies in this meta-analysis

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Country</th>
<th>No</th>
<th>Subjects characteristics</th>
<th>Treatment</th>
<th>Control</th>
<th>Duration (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bobrie (27)</td>
<td>2012</td>
<td>France</td>
<td>290</td>
<td>Patients with inadequately controlled hypertension (SBP of 145–180 mmHg) after 4 weeks of amlodipine 5 mg treatment</td>
<td>Irbesartan 150 mg + amlodipine 5-10 mg</td>
<td>Amlodipine 5 mg</td>
<td>10</td>
</tr>
<tr>
<td>Kang (28)</td>
<td>2011</td>
<td>Korea</td>
<td>185</td>
<td>Patients with inadequately controlled hypertension (DBP &gt;90 mmHg) after 4 weeks of amlodipine 5 mg treatment</td>
<td>Amlodipine 5 mg + losartan 50 mg</td>
<td>Amlodipine 10 mg</td>
<td>8</td>
</tr>
<tr>
<td>Neldam (30)</td>
<td>2011</td>
<td>Europe</td>
<td>544</td>
<td>Patients (DBP &gt;95 mmHg or treatment-naïve patients with DBP &gt;100 mmHg) with inadequately controlled hypertension (DBP &gt;90 mmHg) with 6 weeks of amlodipine 5 mg treatment</td>
<td>Amlodipine 5 mg + telmisartan 80 mg</td>
<td>Amlodipine 5 mg</td>
<td>8</td>
</tr>
<tr>
<td>Neldam (25)</td>
<td>2011</td>
<td>Europe</td>
<td>634</td>
<td>Patients (DBP &gt;95 mmHg or treatment-naïve patients with DBP &gt;100 mmHg) with inadequately controlled hypertension (DBP &gt;90 mmHg) after 6 weeks of amlodipine 10 mg treatment</td>
<td>Amlodipine 10 mg + telmisartan 80 mg</td>
<td>Amlodipine 10 mg</td>
<td>8</td>
</tr>
<tr>
<td>Ke (29)</td>
<td>2010</td>
<td>Asia</td>
<td>698</td>
<td>Patients with inadequately controlled hypertension (msDBP ≥90 mmHg and &lt;110 mmHg) after 4 weeks of amlodipine 5 mg treatment</td>
<td>Amlodipine/valsartan 5/80 mg</td>
<td>Amlodipine 5 mg</td>
<td>8</td>
</tr>
<tr>
<td>Schrader (26)</td>
<td>2009</td>
<td>Europe</td>
<td>1,183</td>
<td>Patients with inadequately controlled hypertension (SBP 130–160 mmHg) after 4 weeks of amlodipine 5 mg treatment</td>
<td>Amlodipine 5 mg + valsartan 160 mg</td>
<td>Amlodipine 10 mg</td>
<td>8</td>
</tr>
<tr>
<td>Volpe (31)</td>
<td>2009</td>
<td>Europe</td>
<td>375</td>
<td>Patients with inadequately controlled hypertension (mean SeDBP &gt;90 mmHg and mean SeSBP &gt;140 mmHg and a mean 24-h DBP &gt;80 mmHg with &gt;30% of day-time readings &gt;85 mmHg) after 8 weeks of amlodipine 5 mg treatment</td>
<td>Amlodipine 5 mg + olmesartan 40 mg</td>
<td>Amlodipine 5 mg</td>
<td>8</td>
</tr>
</tbody>
</table>

SBP, systolic blood pressure; DBP, diastolic blood pressure.

### Table 2 Quality assessment of included studies

<table>
<thead>
<tr>
<th>Author</th>
<th>Random sequence generation</th>
<th>Allocation concealment</th>
<th>Blinding of participants and personnel</th>
<th>Blinding of outcome assessment</th>
<th>Incomplete outcome data</th>
<th>Selective reporting and other bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bobrie (27)</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Kang (28)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Neldam (30)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Neldam (25)</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Ke (29)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Schrader (26)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td>Volpe (31)</td>
<td>Low</td>
<td>Unknown</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
</tbody>
</table>
Figure 2 Effects of ARB + CCB and CCB on BP normalization rate, based on a random-effects model. ARB, angiotensin receptor blocker; CCB, calcium channel blocker; BP, blood pressure.

Figure 3 Effects of ARB + CCB and CCB on BP response rate, based on a random-effects model. (A) SBP response rate; (B) DBP response rate. ARB, angiotensin receptor blocker; CCB, calcium channel blocker; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.

treatment was defined as SBP ≤140 mmHg and the response of DBP to drug treatment was defined as DBP ≤90 mmHg or decrease of DBP ≥10 mmHg after randomization.

Four studies (25,27,28,30) reported the response rate of SBP. Figure 3A summarizes the response rate of SBP using a random effects model. This analysis included a total of 1,604 subjects, including 792 subjects in the amlodipine group and 812 subjects in the amlodipine + ARB group. The response rate of SBP was significantly higher in the amlodipine + ARB group than in the amlodipine monotherapy group (RR =1.28; 95% CI, 1.04–1.58; P<0.01). There was significant heterogeneity among the five studies (I²=0.85).

Four studies (25,28-30) reported the response rate of DBP. Figure 3B summarizes the response rate of DBP using a random effects model. This analysis included a total of 1,980 subjects, including 982 subjects in the amlodipine group and 998 subjects in the combination therapy group. Compared with amlodipine monotherapy, the response rate of DBP was significantly higher in hypertension patients receiving amlodipine + ARB (RR =1.27; 95% CI, 1.12–1.44; P=0.04). There was significant heterogeneity among the four studies (I²=0.64).
**Changes in blood pressure**

Of the 7 studies included, 3 studies (27-29) reported changes in blood pressure before and after randomized treatment. Figure 4A,B summarizes the change of SBP and DBP after randomization. The two analyses included a total of 545 subjects, including 283 subjects in the amlodipine and 272 subjects in the combination therapy group.

Figure 4A showed that, compared with amlodipine monotherapy, the change in SBP was higher in hypertensive patients receiving amlodipine + ARB (RR =−3.56; 95% CI, −7.76–0.63), but the difference did not reach statistical significance (P=0.10). There was significant heterogeneity among the three studies (I²=86%).

**Primary safety endpoint: adverse events**

**Figure 5** summarizes the results of adverse events among the different studies. A fixed effects model was used to compile the results because heterogeneity was small among the 7 studies (I²=9%). ARB + amlodipine treatment carried a lower risk of adverse events relative to amlodipine monotherapy (RR =0.88; 95% CI, 0.80–0.96; P<0.01).

**Discussion**

This meta-analysis of 7 RCTs evaluated the improvement in blood pressure control and safety of CCB combined with ARB (RR =−3.03; 95% CI, −6.51–0.45), but the difference did not reach statistical significance (P=0.09). There was significant heterogeneity among the three studies (I²=86%).
ARB following ineffective CCB monotherapy. The results show that for patients with ineffective CCB monotherapy, adding an ARB significantly reduced blood pressure and significantly improved the response rate and the percentage of on-target hypertension treatment. In addition, for patients with ineffective CCB monotherapy, converting to CCB combined with ARB significantly reduced the incidence of adverse events relative to continued CCB monotherapy.

Many clinical studies and reviews have reported that for patients with ineffective CCB monotherapy, converting to CCB combined with ARB was safe and effective. The present study is the first meta-analysis of such studies. To ensure quality, this meta-analysis included only RCTs and excluded cohort studies.

Consistent with previous studies, this meta-analysis showed that CCB combined with ARB improved blood pressure control in patients with ineffective CCB monotherapy. Previous cohort studies (18) showed that for patients with ineffective CCB monotherapy, converting to CCB combined with ARB improved blood pressure control without increasing the incidence of adverse events; however, these studies did not include a control group and, thus, were unable to reach a definitive conclusion about whether CCB combined with ARB was superior to CCB monotherapy. Several RCTs (32-35) assigned treatment-naïve hypertension patients directly to the CCB monotherapy group or to the CCB combined with ARB group without having an initial screening period with CCB monotherapy; thus, these studies reached the conclusion that CCB combined with ARB was superior to CCB monotherapy in reducing blood pressure, but were unable to clarify whether CCB combined with ARB may improve blood pressure in patients with initial ineffective CCB monotherapy. In this meta-analysis, all selected RCTs enrolled patients with initial ineffective CCB monotherapy who were randomly assigned to the combination therapy group or to the monotherapy group. Therefore the results of this meta-analysis specifically demonstrate adding ARB to CCB improved blood pressure control in patients with ineffective initial CCB monotherapy.

Regarding safety, this meta-analysis showed that CCB combined with ARB significantly reduced the incidence of adverse events relative to CCB monotherapy. In addition to improvements in blood pressure, safety benefits were also derived from other clinical benefits independent of improvements in blood pressure. Previous studies have shown that for hypertensive patients whose blood pressure is 115/75–185/115 mmHg, the risk of death related to cardiovascular complications doubles with each increase of 20 mmHg in SBP or each increase of 10 mmHg in DBP (36); therefore, reducing blood pressure can significantly improve the prognosis of patients with cardiovascular and cerebrovascular diseases. Further, studies have shown that in addition to blood pressure-lowering, patients also benefit from pleiotropic effect during ARB and CCB treatment. ARBs are associated with cardiac and renal protective and reduced incidence of stroke (37,38). CCBs have anti-atherosclerotic effects and reduce the incidence of cardiovascular and cerebrovascular events (14). Studies have shown that ARB combined with CCB reduced the incidence of cardiovascular and cerebrovascular events (39-41). The results of this meta-analysis are consistent with the data from previous studies.

This meta-analysis included only RCTs, which, to a certain extent, ensured rigorous analysis. Nevertheless, this meta-analysis has some limitations. (I) The drug in CCBs group is only amlodipine, whether other kinds of CCBs have the same function remains unknown. (II) The studies included were characterized by different treatment durations, which may affect treatment outcome. (III) Different doses of ARB and CCB were used for combination therapy; therefore, the safety and effectiveness of different doses needs further validated. (IV) Different ARBs and CCBs were used in different studies, which increased the level of heterogeneity in this meta-analysis. However, the number of eligible RCTs would be greatly limited if only RCTs using a particular ARB or CCB were included. Thus, more clinical studies are needed to evaluate the efficacy of combination therapy using specific ARB(s) or CCB(s). (V) Studies have shown that a fixed formulation of ARB + CCB was superior to one ARB (randomly) combined with one CCB (42). Among the studies included in this meta-analysis, six studies used a fixed formulation of ARB + CCB, and four studies used one ARB (randomly) combined with one CCB. We did not compare the treatment outcomes between these two combination regimens. (VI) Regarding safety, this meta-analysis only analyzed adverse events and did not analyze the effects of combination therapy on blood chemistry.

Future research should further investigate the following topics to provide a stronger basis for precise diagnosis and treatment of hypertension. (I) The safety and efficiency of ARB(s) + CCB(s) therapy using different doses, different treatment durations, and different drugs should be evaluated. (II) The advantages of fixed formulation(s) of...
ARB + CCB over one ARB (randomly) combined with one CCB should be explored. (III) The safety and efficiency of ARB + CCB in high-risk and medium-to-low-risk patients, different races, different age groups, and different genders should be evaluated. (IV) In addition to adverse events, the safety of ARB + CCB should also be evaluated based on blood chemistry. (V) Studies have shown that ARB + CCB reduced the risk of cardiovascular events and the incidence of stroke, and future studies should evaluate cardiovascular and cerebrovascular benefits in addition to improved blood pressure.

**Conclusions**

The results of our meta-analysis demonstrate that adding an ARB to CCB after initial ineffective CCB monotherapy, significantly improved blood pressure control and the percentage of on-target hypertension treatment with significantly reduced incidence of adverse events compared with continued CCB monotherapy.

**Acknowledgements**

None.

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

**References**


